CN104519879B - 使用类视色素激动剂治疗中性粒细胞减少症的方法 - Google Patents

使用类视色素激动剂治疗中性粒细胞减少症的方法 Download PDF

Info

Publication number
CN104519879B
CN104519879B CN201380041537.6A CN201380041537A CN104519879B CN 104519879 B CN104519879 B CN 104519879B CN 201380041537 A CN201380041537 A CN 201380041537A CN 104519879 B CN104519879 B CN 104519879B
Authority
CN
China
Prior art keywords
day
neutropenia
tamibarotene
composition
neutrophils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380041537.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104519879A (zh
Inventor
L·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children's Hospital of Los Angeles
Original Assignee
Children's Hospital of Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Hospital of Los Angeles filed Critical Children's Hospital of Los Angeles
Publication of CN104519879A publication Critical patent/CN104519879A/zh
Application granted granted Critical
Publication of CN104519879B publication Critical patent/CN104519879B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380041537.6A 2012-06-07 2013-06-07 使用类视色素激动剂治疗中性粒细胞减少症的方法 Expired - Fee Related CN104519879B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
US61/656,815 2012-06-07
PCT/US2013/044828 WO2013185105A1 (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Publications (2)

Publication Number Publication Date
CN104519879A CN104519879A (zh) 2015-04-15
CN104519879B true CN104519879B (zh) 2018-10-02

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380041537.6A Expired - Fee Related CN104519879B (zh) 2012-06-07 2013-06-07 使用类视色素激动剂治疗中性粒细胞减少症的方法

Country Status (13)

Country Link
US (1) US11116738B2 (enExample)
EP (1) EP2858636B1 (enExample)
JP (1) JP6295249B2 (enExample)
KR (1) KR102083046B1 (enExample)
CN (1) CN104519879B (enExample)
AU (1) AU2013270674B2 (enExample)
BR (1) BR112014030279A2 (enExample)
CA (1) CA2874850A1 (enExample)
ES (1) ES2691493T3 (enExample)
MX (1) MX365321B (enExample)
NZ (1) NZ702415A (enExample)
RU (1) RU2650962C2 (enExample)
WO (1) WO2013185105A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2858636B1 (en) 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
EP2969031A4 (en) 2013-03-15 2017-03-08 Avisenna Cosmetics LLC Topical compositions for reducing aging effects
MX2016010699A (es) * 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.
EP3277272B1 (en) * 2015-03-31 2021-08-04 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-agonists
KR20240157122A (ko) 2016-04-08 2024-10-31 사이로스 파마수티컬스, 인크. Aml 및 mds 치료용 rara 효능제
TW201823471A (zh) * 2016-10-06 2018-07-01 美商錫羅斯製藥公司 以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法
US20210123021A1 (en) * 2018-01-26 2021-04-29 Agency For Science, Technology And Research Neutrophil subtypes
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY
WO2025250787A2 (en) * 2024-05-30 2025-12-04 The Children's Medical Center Corporation Compositions and methods for treating sepsis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641091A (zh) * 2007-03-30 2010-02-03 Tmrc株式会社 他米巴罗汀胶囊剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
CA2273288A1 (en) * 1996-12-19 1998-06-25 James Joseph Gibbons Method of treating or inhibiting neutropenia
AU9084601A (en) 2000-09-08 2002-03-22 Massachusetts Inst Technology G-csf analog compositions and methods
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2004100972A1 (ja) 2003-05-16 2004-11-25 Kyowa Hakko Kogyo Co., Ltd. 組織破壊を伴う疾患の予防及び／または治療剤
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
RS51506B (sr) 2004-12-02 2011-06-30 Venus Remedies Limited H. O&R&D. Smeše za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike upotrebom inhibitora beta-laktamaze, korisne za injekcije
WO2006071451A2 (en) * 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
CN101472572B (zh) 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
JP2011505386A (ja) * 2007-12-06 2011-02-24 シーエスエル、リミテッド 白血病性幹細胞の阻害方法
US8580516B2 (en) 2008-09-05 2013-11-12 University Of Chicago Methods and compositions for direct detection of DNA damage
AU2010309388B2 (en) 2009-10-19 2016-03-10 Laila Nutraceuticals Extracts, fractions and compositions comprising acetogenins and their applications
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
EP2847198B1 (en) * 2012-05-08 2016-12-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease
EP2858636B1 (en) 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641091A (zh) * 2007-03-30 2010-02-03 Tmrc株式会社 他米巴罗汀胶囊剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The effects of retinoic Acid analogs on the blast cells of acute myeloblastic-leukemia in culture;Tohda S等;《Int J Oncol.》;19940630;第4卷(第6期);第1311-1314页 *
维甲酸对急性早幼粒细胞白血病白血病细胞诱导分化作用的研究;毕卫真等;《中国医科大学学报》;19911231;第20卷(第2期);第151-155页 *

Also Published As

Publication number Publication date
RU2650962C2 (ru) 2018-04-18
ES2691493T3 (es) 2018-11-27
NZ702415A (en) 2016-04-29
BR112014030279A2 (pt) 2017-09-12
EP2858636A4 (en) 2016-06-01
MX2014014930A (es) 2015-07-06
KR20150035983A (ko) 2015-04-07
US20150164836A1 (en) 2015-06-18
RU2014153988A (ru) 2016-07-27
JP6295249B2 (ja) 2018-03-14
MX365321B (es) 2019-05-29
EP2858636B1 (en) 2018-09-05
CA2874850A1 (en) 2013-12-12
AU2013270674B2 (en) 2017-12-07
AU2013270674A1 (en) 2014-12-18
CN104519879A (zh) 2015-04-15
WO2013185105A1 (en) 2013-12-12
KR102083046B1 (ko) 2020-02-28
HK1208630A1 (en) 2016-03-11
JP2015523346A (ja) 2015-08-13
EP2858636A1 (en) 2015-04-15
US11116738B2 (en) 2021-09-14

Similar Documents

Publication Publication Date Title
EP2858636B1 (en) Methods for treating neutropenia using retinoid agonists
JP6695286B2 (ja) リンパ腫の処置
JP2022172262A (ja) 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
JP2021513853A (ja) 癌免疫療法のためのチェックポイント遮断としての操作されたナノベシクル
EA037117B1 (ru) Новая фармацевтическая композиция, содержащая частицы, содержащие комплекс двухнитевого полирибонуклеотида и полиалкиленимина
Tabansky et al. Advancing drug delivery systems for the treatment of multiple sclerosis
EP2978439B1 (en) A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia
JP2019503386A (ja) 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
US20260048083A1 (en) Method of treating alzheimer's disease with expanded natural killer cells
Ahmad et al. Deciphering the enigma of neuron-glial interactions in neurological disorders
CA2155920A1 (en) Use of interferon for the inhibition of proliferation and differentiation of primitive hematopoietic progenitor cells
ES2789574T3 (es) Modulación de la activación del inflamasoma de células supresoras derivadas de mieloides para el tratamiento de GvHD o tumor
US20230330193A1 (en) Enhancement of stem cell therapy for cartilage degeneration by anti-oxidant pre-conditioning
CN117159525A (zh) Cert抑制剂在制备治疗急性髓系白血病的药物中的应用
HK1208630B (en) Methods for treating neutropenia using retinoid agonists
CN116829142A (zh) 处理和改善癌症的方法
EP4578454A1 (en) Compositions comprising platelet derived extracellular vesicles
WO2025059662A1 (en) Artificial antigen presenting cells to improve t cell function
HK40077184A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
CN118236361A (zh) 牛磺酸联合化疗药物在制备抗肿瘤药物中的应用
HK1215790B (en) A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia
HK1226332B (en) A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation
HK1226332A1 (en) A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181002